Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriatic arthritis

ACR/ARHP Annual Meeting 2012: Late-Breaking Abstracts Bring Newer Research to the Forefront

Mary Beth Nierengarten  |  January 1, 2013

Studies addressing rheumatoid arthritis (RA) flares, a potential new drug for psoriatic arthritis, and a novel agent in the treatment of active RA are among the highlights

Filed under:ConditionsMeeting ReportsPsoriatic ArthritisRheumatoid Arthritis Tagged with:ACR/ARHP Annual MeetingPsoriatic ArthritisRA flaresRheumatoid arthritis

Treatment Patterns and Trends for Spondylarthropathies

Vanessa Caceres  |  April 6, 2012

Methotrexate is a commonly used disease-modifying antirheumatic drug (DMARD) for treating patients with psoriatic arthritis (PsA). However, is it truly as effective as many think it is? That’s the question raised during the session “Spondylarthropathies: Recent Insights,” which took place at the 2011 ACR/ARHP Annual Scientific Meeting in November.

Filed under:Axial SpondyloarthritisConditionsDrug UpdatesPsoriatic Arthritis Tagged with:ACR/ARHP Annual MeetingAnkylosing Spondylitisanti-inflammatorydrugGlucocorticoidsMethotrexatepatient carePsoriatic ArthritisReactive arthritisRheumatoid arthritis

JAK Inhibitors 101

Jason Liebowitz, MD, FACR  |  July 28, 2025

Experts provided an in-depth review of Janus kinase (JAK) inhibitors, discussing the latest research on their use in the treatment of specific rheumatic conditions, the risks associated with them and more.

Filed under:Biologics/DMARDsConditionsDrug UpdatesEULAR/OtherGuidanceMeeting Reports Tagged with:EULAR 2025JAK inhibitorsJanus Kinase Inhibitors

Finding the Panacea

Jason Liebowitz, MD, FACR  |  July 16, 2025

Janus kinase (JAK) inhibitors, biologics and more—Dr. Laura Coates discussed the management of PsA, providing insights into the current research and when clinicians may want to consider prescribing specific medications.

Filed under:ConditionsEULAR/OtherGuidanceMeeting ReportsPsoriatic Arthritis Tagged with:Axial Psoriatic Arthritis (axPsA)EULAR 2025PsAPsA Resource CenterPsoriatic Arthritisskin

Rheumatology Influencers: Dr. Christopher Morris’ Approach to Leadership

Linda Childers  |  July 10, 2025

Dr. Christopher Morris discusses his approach to training the next generation of rheumatologists to account for disparities in access to rheumatic care& the value of multidisciplinary medical organizations.

Filed under:Profiles Tagged with:AdvocacyDr. Christopher MorrisLeadershipMentorPrivate practiceRheumatology InfluencersWorkforceworkforce shortageWorkforce Solutions Committee

New Study: Upadacitinib Is Treatment Option for Giant Cell Arteritis

Deborah Levenson  |  July 10, 2025

Results of the international SELECT-GCA study suggest that upadacitinib may be an effective new oral treatment for giant cell arteritis.

Filed under:Biologics/DMARDsConditionsDrug UpdatesResearch RheumVasculitis Tagged with:AAV FocusRheumActemraGCAGiant Cell ArteritisGlucocorticoidsJAK inhibitorsJanus Kinase InhibitorsprednisoneRINVOQtocilizumabupadacitinib

Doctoring Differently, Part 2

Samantha C. Shapiro, MD  |  July 9, 2025

In part 2 of Dr. Sam Shapiro’s journey, learn how she connected with the rheumatology community to change her career and found a better way to embrace her passions for clinical rheumatology, education and helping patients.

Filed under:CareerOpinion Tagged with:CareerClinical PracticeeConsultEducationProfile

FDA Approves Upadacitinib for GCA

Michele B. Kaufman, PharmD, BCGP  |  June 16, 2025

Supported by data in patients with new-onset and relapsing giant cell arteritis (GCA), the FDA approved upadacitinib for the treatment of adults with GCA.

Filed under:Biologics/DMARDsConditionsDrug UpdatesVasculitis Tagged with:FDA approvalGCAgiant cell arteritis (GCA)U.S. Food and Drug Administration (FDA)upadacitinib

Incarcerated Individuals with Rheumatic Conditions

Katherine Terracina, MD, & Prajakta P. Masurkar, PhD  |  June 8, 2025

In addition to the impediments to consistent, high-quality care suffered by all incarcerated individuals, incarcerated patients with rheumatic disease face challenges specific to the treatment, management & monitoring of rheumatic conditions.

Filed under:EthicsGuidance Tagged with:Chronic disease managementethical considerationsEthics Forumhealth disparitieshealthcare policymedication accesspatient advocacyprison healthcaretelemedicine

Editor's Pick

Incorporating Patient-Reported Outcomes into the Clinic

Katie Robinson  |  May 5, 2025

‘Measuring patient-reported outcomes (PROs) is an important component of high-quality, patient-centered care, but integration of PROs into clinic can be challenging,’ says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘Luckily, tools exist to help us realize this vital aspect of patient care.’ The ACR’s quality measures for care include gauging disease activity and…

Filed under:EMRsPatient PerspectivePractice Support Tagged with:patient reported outcomes

  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 63
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences